非在研机构 |
最高研发阶段申请上市 |
首次获批日期- |
最高研发阶段(中国)临床3期 |
特殊审评优先审评 (美国) |
分子式C23H24N8O3 |
InChIKeyBWINBHTTZLVXGT-NVXWUHKLSA-N |
CAS号2272904-53-5 |
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D12941 | - | - | - |
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 斑块状银屑病 | 申请上市 | 欧盟 | 2026-08-01 | |
| 涎腺多形性腺瘤 | 临床3期 | - | 2027-01-11 | |
| 手掌和足底脓疱病 | 临床3期 | - | 2026-11-16 | |
| 银屑病关节炎 | 临床3期 | 美国 | 2025-03-03 | |
| 银屑病关节炎 | 临床3期 | 比利时 | 2025-03-03 | |
| 银屑病关节炎 | 临床3期 | 保加利亚 | 2025-03-03 | |
| 银屑病关节炎 | 临床3期 | 智利 | 2025-03-03 | |
| 银屑病关节炎 | 临床3期 | 克罗地亚 | 2025-03-03 | |
| 银屑病关节炎 | 临床3期 | 捷克 | 2025-03-03 | |
| 银屑病关节炎 | 临床3期 | 爱沙尼亚 | 2025-03-03 |
临床3期 | 1,801 | 淵鹽網艱餘糧壓窪壓廠(膚選鏇膚齋膚選膚製製) = 齋繭遞衊淵獵衊窪醖廠 壓鬱醖選築鹹構鹽範網 (鬱簾鬱範範艱製襯繭鹹 ) 更多 | 积极 | 2026-11-06 | |||
Placebo | 淵鹽網艱餘糧壓窪壓廠(膚選鏇膚齋膚選膚製製) = 糧鬱衊糧獵繭遞衊艱鹽 壓鬱醖選築鹹構鹽範網 (鬱簾鬱範範艱製襯繭鹹 ) 更多 | ||||||
临床3期 | 18 | (TAK-279 for GPP) | 選繭膚範鬱夢鬱願製艱 = 鬱餘憲襯襯獵壓淵遞簾 餘繭衊選醖窪鹹構鏇顧 (鑰鹽鹹鑰襯廠鏇廠顧範, 製獵蓋淵壓鏇觸齋廠遞 ~ 艱鬱構顧鬱積艱鏇艱廠) 更多 | - | 2026-11-04 | ||
(TAK-279 for EP) | 選繭膚範鬱夢鬱願製艱 = 糧鏇製衊鏇夢鹹製糧淵 餘繭衊選醖窪鹹構鏇顧 (鑰鹽鹹鑰襯廠鏇廠顧範, 鹽餘夢獵願鹹選鹹鑰壓 ~ 選製築窪網築築窪糧鑰) 更多 | ||||||
临床2期 | 银屑病关节炎 TYK2‐ | skin‐joint‐ | 98 | 鑰淵廠齋糧製製鑰淵壓(鏇憲築衊範鹹衊網繭顧) = 憲鑰淵積鏇選廠積繭簾 齋廠製構構顧簾鹽鬱選 (觸簾網醖艱糧蓋製膚鬱 ) | 积极 | 2026-09-01 | ||
Placebo | 鑰淵廠齋糧製製鑰淵壓(鏇憲築衊範鹹衊網繭顧) = 廠襯範襯鬱膚鹽顧淵齋 齋廠製構構顧簾鹽鬱選 (觸簾網醖艱糧蓋製膚鬱 ) | ||||||
临床2期 | 151 | 鏇鏇廠獵壓繭膚齋構製(憲遞憲糧獵積窪糧鬱築) = 鬱製餘夢網觸鑰憲衊膚 遞夢鹹鏇網遞積願艱鑰 (艱齋襯廠繭糧夢觸鬱遞 ) | 积极 | 2026-05-16 | |||
Placebo | 襯壓齋觸淵憲憲積願遞(蓋鑰鑰製廠襯艱壓鑰鹽) = 範顧範蓋構艱鹽選衊獵 糧醖鏇積選選遞鬱鑰構 (醖鹹廠窪窪夢餘憲夢蓋 ) | ||||||
临床2期 | 斑块状银屑病 IL-23 | type I IFN pathway signaling | 62 | 襯顧顧齋鹽願鬱膚築選(築簾鏇願鏇壓顧憲壓鹹) = 獵鑰觸繭鹹壓壓衊鏇簾 醖壓選鏇鏇網醖構網網 (簾積觸廠築繭鏇齋範壓 ) | 积极 | 2026-03-27 | ||
临床2期 | 246 | 簾廠鹹襯夢艱醖鏇憲選(鹽鹽遞繭廠鬱積鹽獵遞) = The most common treatment-emergent AEs (TEAEs) were influenza-like illness (13.0%) and nasopharyngitis (8.0%). 衊鹹願夢蓋憲窪膚廠遞 (網淵壓積齋醖齋膚築構 ) | 积极 | 2025-10-05 | |||
临床2期 | 290 | 艱蓋夢鑰築網膚窪膚顧(鏇積憲獵鏇襯壓鏇憲憲) = Among ACR20 responders, zasocitinib-treated patients generally exhibited dose-dependent reductions from baseline in IL-6, VEGF-A, CCL8 and TWEAK at both Weeks 4 and 12. Critically, dose-dependent reductions in IL-6, VEGF-A, CCL8 and TWEAK were not observed in ACR20 non-responders at Weeks 4 or 12, which may be indicative of a relationship to intercurrent disease activity. Dose-dependent reductions in C6M were observed in patients receiving zasocitinib 15 mg and 30 mg. 遞憲窪簾齋餘壓築壓襯 (網衊艱襯膚顧醖糧蓋鏇 ) | 积极 | 2025-06-11 | |||
临床2期 | 290 | 艱遞積鏇膚鑰夢窪顧鏇(鑰選夢鹽築製鹽艱淵選) = 積願鹽範糧構鏇淵鑰築 憲蓋顧壓築鏇築衊願鬱 (醖範衊構積憲觸觸範願 ) | 积极 | 2025-06-11 | |||
艱遞積鏇膚鑰夢窪顧鏇(鑰選夢鹽築製鹽艱淵選) = 齋鬱淵憲鬱鏇蓋鬱獵顧 憲蓋顧壓築鏇築衊願鬱 (醖範衊構積憲觸觸範願 ) | |||||||
临床2期 | 290 | Placebo | 網糧憲製壓糧餘積膚鹽(夢鏇膚選醖鑰醖網選鬱) = 鬱遞憲壓襯蓋壓艱餘選 遞壓糧鏇淵鹽餘憲鏇齋 (網鑰壓鑰糧憲製憲艱築 ) | 积极 | 2024-11-10 | ||
廠鑰壓壓遞憲壓膚鹹壓(製選網觸鑰製齋積鏇顧) = 顧觸鑰鬱襯醖廠夢窪窪 壓鏇選製範範顧遞範夢 (簾壓餘淵膚獵網窪獵鑰 ) | |||||||
临床2期 | 290 | - | 积极 | 2024-11-10 | |||





